Canopus Medical AB has contracted OPERA CRO to conduct its clinical trials in Europe
Canopus Medical AB today announced that the company has entered an agreement for clinical services with the global contract research organization (CRO) OPERA, for the planning and execution of its clinical studies. The studies will cover all three dermal filler products and the visco-supplementation product for knee osteoarthritis. All four products are medical device Class III products.
According to the agreement, the first patient in each study will be enrolled during the first quarter of 2023 and the objective is to have top line results from the study in the second quarter of 2023. The study will be conducted at 1-2 European qualified sites.
Ali Ismail, CEO of Canopus Medical:
“We are very pleased to have OPERA as our partner for these important trials with our special hyaluronic acid complexes, our lead medical device candidates. Opera is a leading global CRO with considerable experience in medical devices. Our goal is, while maintaining the products´ safety profile from the trials, to achieve a commercial manufacturing capacity in our production site”.
For more information: Ali Ismail, CEO, Phone: +46 708 188558
About Canopus Medical AB
Canopus Medical AB is a Swedish cooperation, aims to provide the capacity to develop and produce innovative cosmeceutical products, for research and commercial purposes. Beside developing and commercializing its own label product line, Canopus Medical also provides B2B opportunities to support the discovery, development and manufacturing of medical devices and cosmetic products.
About Opera CRO
Opera CRO is a contract research organization with over 25 years of experience in clinical research for drugs, medical devices, and food supplements. Headquartered in Romania and with local offices in Eastern and Western European countries, Opera CRO has successfully supported hundreds of companies to develop new products. Opera is the subsidiary of TIGERMED, the leading CRO in China, and acts as a bridge between its European clients and the Chinese market.